Loading clinical trials...
Loading clinical trials...
A Phase 2, Double-blind, Randomized, Multicenter, Placebo-controlled, Three Arm Parallel Study to Evaluate the Efficacy and Safety of TNX-1900 (Intranasal Oxytocin) in Patients With Chronic Migraine (PREVENTION Study)
Conditions
Interventions
TNX-1900
Placebo Nasal Spray
Locations
26
United States
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Synergy Research Centers - Synergy San Diego
Lemon Grove, California, United States
Excell Research
Oceanside, California, United States
Viking Clinical Research, LTD
Temecula, California, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Segal Trials - Miami Lakes Medical Research Outpatient Site
Miami Lakes, Florida, United States
Start Date
December 6, 2022
Primary Completion Date
October 8, 2023
Completion Date
October 23, 2023
Last Updated
February 25, 2025
NCT07018713
NCT04715685
NCT06810505
NCT06554886
NCT05337033
NCT03404336
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions